Cingulate (CING) EBT Growth (1y) (2022 - 2026)
Cingulate (CING) EBT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 88.57% |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 6.23% |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 213.87% |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 530.43% |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -182.24% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.45% |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | -12.04% |
| 10 | Cingulate | 71.34 Mn | 71.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.80% |
| Dec 31, 2025 | -0.67% |
| Sep 30, 2025 | -77.94% |
| Mar 31, 2025 | -27.93% |
| Dec 31, 2024 | 10.15% |
| Sep 30, 2024 | 31.00% |
| Jun 30, 2024 | 51.49% |
| Mar 31, 2024 | 25.78% |
| Dec 31, 2023 | -50.59% |
| Sep 30, 2023 | -48.47% |
| Jun 30, 2023 | -63.75% |
| Mar 31, 2023 | 19.96% |
| Dec 31, 2022 | -73.53% |
| Sep 30, 2022 | 73.66% |
| Jun 30, 2022 | -182.10% |
| Mar 31, 2022 | -275.10% |